LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 849

Search options

  1. Article ; Online: Obesity management from the perspectives of people living with obesity in Canada: A mixed-methods study.

    Lau, David C W / Patton, Ian / Lavji, Reena / Belloum, Adel / Ng, Ginnie / Modi, Renuca

    Diabetes, obesity & metabolism

    2024  Volume 26, Issue 4, Page(s) 1529–1539

    Abstract: Aims: To identify and better understand themes related to why people living with obesity (PwO) in Canada may not use professional support and to explore potential strategies to address the challenges.: Methods: One-on-one interviews and online ... ...

    Abstract Aims: To identify and better understand themes related to why people living with obesity (PwO) in Canada may not use professional support and to explore potential strategies to address the challenges.
    Methods: One-on-one interviews and online surveys, informed by the Theoretical Domains Framework, were conducted. A total of 20 PwO were interviewed and a separate group of 200 PwO were surveyed. Results from the interviews guided the development of the survey. Spearman's correlation analysis was performed to investigate the association between the theme domain scores of the PwO and their prior experience with obesity management strategies.
    Results: The 200 PwO surveyed provided representation across Canada and were diverse in age, background and gender. The most prominent domains associated with use of professional support by PwO were: Intention (r
    Conclusion: This study identified contextual, perception and resource considerations that contribute to healthcare decision-making and the use by PwO of professional support to manage obesity, and highlighted key areas to target with interventions to facilitate obesity management. Strategies such as consistent access to healthcare support and educational resources, as well as improved financial support may help PwO to feel more comfortable with exploring new strategies and take control of their healthcare.
    MeSH term(s) Humans ; Obesity Management ; Obesity/epidemiology ; Obesity/therapy ; Canada/epidemiology ; Delivery of Health Care ; Surveys and Questionnaires
    Language English
    Publishing date 2024-01-29
    Publishing country England
    Document type Journal Article
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Are Postoperative Complications of Joint Replacement Correlated With the Phase of the Moon? An Analysis of Data From the Medicare Registry.

    Walter, Nike / Hinterberger, Thilo / Loew, Thomas / Lowenberg, David W / Alt, Volker / Lau, Edmund C / Rupp, Markus

    Deutsches Arzteblatt international

    2024  Volume 120, Issue 51-52, Page(s) 888–889

    MeSH term(s) Aged ; Humans ; Arthroplasty, Replacement/adverse effects ; Medicare ; Moon ; Postoperative Complications/epidemiology ; Registries ; United States/epidemiology
    Language English
    Publishing date 2024-02-05
    Publishing country Germany
    Document type Letter
    ZDB-ID 2406159-1
    ISSN 1866-0452 ; 1866-0452
    ISSN (online) 1866-0452
    ISSN 1866-0452
    DOI 10.3238/arztebl.m2023.0249
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Canadian Journal of Diabetes Welcomes a New Editor-In-Chief.

    Lau, David C W

    Canadian journal of diabetes

    2017  Volume 41, Issue 5, Page(s) 467–468

    MeSH term(s) Canada ; Diabetes Mellitus ; Editorial Policies ; Humans ; Periodicals as Topic ; Publishing
    Language English
    Publishing date 2017-09-25
    Publishing country Canada
    Document type Editorial
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2017.08.245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.

    Lau, David C W / Batterham, Rachel L / le Roux, Carel W

    Expert review of clinical pharmacology

    2022  Volume 15, Issue 3, Page(s) 251–267

    Abstract: Introduction: The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly injectable semaglutide 2.4 mg, as an adjunct ...

    Abstract Introduction: The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly injectable semaglutide 2.4 mg, as an adjunct to a calorie-controlled diet and increased physical activity, for chronic weight management provides health-care practitioners with an additional option when prescribing weight-loss medication.
    Areas covered: We describe the chemistry, mechanism of action, and pharmacological properties of semaglutide (a glucagon-like peptide 1 receptor agonist [GLP-1 RA]) and discuss clinical data and considerations for using once-weekly subcutaneous semaglutide 2.4 mg as treatment for overweight and obesity among patients with and without type 2 diabetes (T2D).
    Expert opinion: Once-weekly subcutaneous semaglutide 2.4 mg is the most efficacious medication approved for chronic weight management among patients with overweight and obesity, with and without T2D, and is the first drug to induce sustained double-digit reductions in percentage body weight over 1- to 2-year treatment periods. It demonstrates a similar safety and tolerability profile to other GLP-1 RAs. Semaglutide 2.4 mg treatment could dramatically improve clinical approaches to weight management, but the relatively high cost might prevent patients accessing treatment. Further research exploring the cost-effectiveness of subcutaneous semaglutide 2.4 mg is required.
    MeSH term(s) Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptides/pharmacology ; Glucagon-Like Peptides/therapeutic use ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Obesity/drug therapy ; Overweight/chemically induced ; Overweight/drug therapy ; Pharmaceutical Preparations
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Pharmaceutical Preparations ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8) ; Glucagon-Like Peptide 1 (89750-14-1)
    Language English
    Publishing date 2022-04-27
    Publishing country England
    Document type Journal Article
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2022.2070473
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Diabetes Canada and the Canadian Journal of Diabetes Affirm Their Mission to End Diabetes.

    Lau, David C W

    Canadian journal of diabetes

    2017  Volume 41, Issue 2, Page(s) 121–122

    MeSH term(s) Canada ; Diabetes Mellitus/prevention & control ; Humans ; Periodicals as Topic ; Research Report/standards
    Language English
    Publishing date 2017-04-10
    Publishing country Canada
    Document type Editorial
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2017.02.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.

    Olivieri, Anamaria-Vera / Muratov, Sergey / Larsen, Sara / Luckevich, Maria / Chan, Katalina / Lamotte, Mark / Lau, David C W

    International journal of obesity (2005)

    2024  Volume 48, Issue 5, Page(s) 683–693

    Abstract: Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the ... ...

    Abstract Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the current standard of care (SoC).
    Methods: Analyses were conducted using a cohort with a mean starting age 50 years, body mass index (BMI) 37.5 kg/m
    Results: From a societal perspective, at a willingness-to-pay (WTP) threshold of CAD 50 000 per QALY, semaglutide 2.4 mg was the most cost-effective treatment, at an incremental cost-utility ratio (ICUR) of CAD 31 243 and CAD 29 014 per QALY gained versus the next best alternative, i.e., orlistat, and SoC, respectively. Semaglutide 2.4 mg extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg and remained cost-effective both under a public and private payer perspective. Results were robust to sensitivity analyses varying post-treatment catch-up rates, longer treatment durations and using real-world cohort characteristics. Semaglutide 2.4 mg was the preferred intervention, with a likelihood of 70% at a WTP threshold of CAD 50 000 per QALY gained. However, when the modeled benefits of weight-loss on cancer, mortality, cardiovascular disease (CVD) or osteoarthritis surgeries were removed simultaneously, orlistat emerged as the best value for money compared with SoC, with an ICUR of CAD 35 723 per QALY gained.
    Conclusion: Semaglutide 2.4 mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.
    MeSH term(s) Humans ; Cost-Benefit Analysis ; Canada ; Middle Aged ; Obesity/drug therapy ; Obesity/economics ; Female ; Anti-Obesity Agents/therapeutic use ; Anti-Obesity Agents/economics ; Male ; Orlistat/therapeutic use ; Quality-Adjusted Life Years ; Liraglutide/therapeutic use ; Liraglutide/economics ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/economics ; Bupropion/therapeutic use ; Bupropion/economics ; Naltrexone/therapeutic use ; Naltrexone/economics ; Glucagon-Like Peptides/therapeutic use ; Glucagon-Like Peptides/economics
    Chemical Substances Anti-Obesity Agents ; Orlistat (95M8R751W8) ; Liraglutide (839I73S42A) ; Bupropion (01ZG3TPX31) ; semaglutide (53AXN4NNHX) ; Naltrexone (5S6W795CQM) ; Glucagon-Like Peptides (62340-29-8)
    Language English
    Publishing date 2024-01-31
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752409-2
    ISSN 1476-5497 ; 0307-0565
    ISSN (online) 1476-5497
    ISSN 0307-0565
    DOI 10.1038/s41366-024-01467-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Conference proceedings: Cellular and molecular biology of adipose cell development and growth

    Lau, David C. W.

    an international symposium 17 - 19 August 1994, the University of Ottawa, Ottawa, Ontario, Canada ; a satellite meeting of the 7th International Congress of Obesity held in Toronto, Ontario, Canada, 20 - 25 August, 1994

    (International journal of obesity and related metabolic disorders ; 20, Suppl. 3)

    1996  

    Event/congress International Congress on Obesity (7, 1994, Toronto)
    Author's details ed. David C. W. Lau
    Series title International journal of obesity and related metabolic disorders ; 20, Suppl. 3
    Collection
    Keywords Adipocytes / cytology / congresses ; Cell Division / congresses ; Adipose Tissue / congresses
    Language English
    Size S130 S. : Ill., graph. Darst.
    Publisher Stockton
    Publishing place Basingstoke
    Publishing country Great Britain
    Document type Book ; Conference proceedings
    HBZ-ID HT007144065
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  8. Article ; Online: Tackling Peer Review: How to Improve Reviews and Minimize Abuse.

    Lau, David C W

    Canadian journal of diabetes

    2016  Volume 40, Issue 2, Page(s) 105–106

    MeSH term(s) Guidelines as Topic/standards ; Humans ; Peer Review ; Review Literature as Topic
    Language English
    Publishing date 2016-04
    Publishing country Canada
    Document type Editorial
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2016.02.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Response to a recently published Letter to the Editor in The Lancet.

    Lau, David C W

    Canadian journal of diabetes

    2015  Volume 39, Issue 1, Page(s) 3

    MeSH term(s) Humans ; Warfare
    Language English
    Publishing date 2015-02
    Publishing country Canada
    Document type Comment ; Editorial
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2014.12.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Diabetes in the Elderly: A Silent Global Tsunami.

    Lau, David C W

    Canadian journal of diabetes

    2016  Volume 40, Issue 1, Page(s) 2–3

    MeSH term(s) Aged ; Aged, 80 and over ; Aging ; Combined Modality Therapy ; Congresses as Topic ; Diabetes Complications/epidemiology ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/epidemiology ; Diabetes Mellitus, Type 1/therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/prevention & control ; Diabetes Mellitus, Type 2/therapy ; Global Health ; Health Transition ; Humans ; Precision Medicine
    Language English
    Publishing date 2016-02
    Publishing country Canada
    Document type Editorial ; Introductory Journal Article
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2015.12.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top